The American Academy of Pediatrics breaks with federal guidance, urging COVID shots for young kids as Kennedy's panel delays ...

The outcome of this study could significantly influence BioNTech’s stock performance and investor sentiment, especially if the combination therapy proves more effective than the standard treatment.

Multiple scientists and doctors have spoken out against this decision, including infectious diseases expert Dr. Thomas A. Russo, who told Newsweek that mRNA vaccines "will be critical when the next, ...

Texas school districts are coming back from summer with a rising number of parents asking for vaccine exemption forms and a ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...

BioNTech ADR earns the No. 143 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals ...

The top executives running the health care industry’s blue-chip companies amassed generational wealth in 2024, even as many ...

Parents won't be able to vaccinate healthy children 6 months to 5 years old if the FDA pulls Pfizer's COVID-19 vaccine ...

Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

Here is how BioNTech SE Sponsored ADR (BNTX) and EUROFINS SCIENT (ERFSF) have performed compared to their sector so far this year.

(Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer ...